Short answer
Lilly (Eli) (LLY) filed its Q2 2025 10-Q quarterly report on Aug 7, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $15.6B (up 37.6% year over year) with net income of $5.7B.
Q2 2025 key financials · XBRL
- Revenue
- $15.6B
- +37.6% YoY · +22.2% QoQ
- Net income
- $5.7B
- +90.8% YoY · +105.1% QoQ
- EPS (diluted)
- $6.29
- +91.8% YoY · +105.6% QoQ
Source: XBRL data from the Lilly (Eli) (LLY) Q2 2025 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash and cash equivalents $3.38B as of June 30, 2025, up from $3.27B Dec 31, 2024
- Total debt $39.90B, increased $6.26B from $33.64B at Dec 31, 2024, driven by $6.50B fixed-rate notes issuance
- Share repurchases $1.89B during six months ended June 30, 2025, $13.11B remaining under $15B program
- Capital expenditures expected to rise significantly due to investments in manufacturing capacity and contract manufacturing agreements up to $8B potential liability
- No specific quarterly revenue or margin figures, no updated profitability metrics or segment performance disclosed
Risk Factors
- Newly added risk: Collaboration amendment with Boehringer Ingelheim triggered one-time $370M Jardiance revenue benefit, affecting future revenue recognition
- Most materially updated risk: Increased R&D expenses by 23% QoQ driven by expanded early and late-stage portfolio investments
- Regulatory risk: Effective tax rate rose to 17.7% for six months ended June 2025 due to nondeductible acquired IPR&D charge from Scorpion acquisition
- Operational risk: Strong demand but lower realized prices for Mounjaro and Zepbound impacting U.S. volume-price dynamics and near-term margins
- Financial risk: Liquidity supported by cash, operating cash flow, and access to borrowings deemed sufficient for current and planned capital needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.